Biorestorative Therapies Inc (BRTX) Stock Price, Quote & News

Latest News on BRTX

Apr 15, 2025, 8:30 AM EDT - 3 days ago

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

Apr 10, 2025, 9:15 AM EDT - 8 days ago

BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States

Mar 27, 2025, 8:10 PM EDT - 22 days ago

BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:45 AM EST - 7 weeks ago

BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

Feb 26, 2025, 8:15 PM EST - 7 weeks ago

BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update

Feb 20, 2025, 8:30 AM EST - 2 months ago

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

Dec 5, 2024, 6:45 AM EST - 4 months ago

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

Nov 13, 2024, 7:53 PM EST - 5 months ago

BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 7:10 AM EST - 5 months ago

BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health

Oct 3, 2024, 4:15 PM EDT - 7 months ago

BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 19, 2024, 6:55 AM EDT - 7 months ago

BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

Aug 13, 2024, 11:26 PM EDT - 8 months ago

BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript

Jul 23, 2024, 7:10 AM EDT - 9 months ago

BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine

Jun 27, 2024, 7:40 AM EDT - 10 months ago

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

Jun 17, 2024, 7:05 AM EDT - 10 months ago

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

Jun 13, 2024, 7:00 AM EDT - 11 months ago

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

Jun 4, 2024, 8:50 AM EDT - 11 months ago

BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference

May 24, 2024, 7:45 PM EDT - 11 months ago

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice

May 15, 2024, 9:00 AM EDT - 1 year ago

BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

May 14, 2024, 7:08 PM EDT - 1 year ago

BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:10 PM EDT - 1 year ago

BioRestorative Therapies Provides First Quarter 2024 Business Update

May 8, 2024, 7:30 AM EDT - 1 year ago

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

Apr 30, 2024, 4:15 PM EDT - 1 year ago

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 30, 2024, 7:30 AM EDT - 1 year ago

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

Apr 16, 2024, 7:45 AM EDT - 1 year ago

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

Apr 8, 2024, 7:45 AM EDT - 1 year ago

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

Apr 3, 2024, 4:38 PM EDT - 1 year ago

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants

Apr 1, 2024, 7:45 AM EDT - 1 year ago

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

Mar 11, 2024, 4:15 PM EDT - 1 year ago

BioRestorative Therapies to Participate in the 36th Annual ROTH Conference

Feb 14, 2024, 9:15 AM EST - 1 year ago

BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting

Feb 6, 2024, 8:05 AM EST - 1 year ago

BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market

Feb 5, 2024, 7:30 AM EST - 1 year ago

BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

Feb 1, 2024, 7:30 AM EST - 1 year ago

BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting

Dec 12, 2023, 9:15 AM EST - 1 year ago

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

Oct 9, 2023, 12:10 PM EDT - 1 year ago

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

Sep 18, 2023, 9:00 AM EDT - 1 year ago

Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”

Sep 12, 2023, 9:00 AM EDT - 1 year ago

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

Sep 8, 2023, 8:30 AM EDT - 1 year ago

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

Aug 30, 2023, 9:00 AM EDT - 1 year ago

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

Aug 2, 2023, 9:00 AM EDT - 1 year ago

BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares

Jul 31, 2023, 8:05 AM EDT - 1 year ago

Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The Discussion

Jul 21, 2023, 7:10 AM EDT - 1 year ago

BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State

Jul 11, 2023, 8:30 AM EDT - 1 year ago

BioRestorative Therapies Announces $2.1 Million Registered Direct Offering

Jul 7, 2023, 7:00 AM EDT - 1 year ago

BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities

Jun 27, 2023, 7:00 AM EDT - 1 year ago

BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes

Jun 16, 2023, 7:00 AM EDT - 2 years ago

BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

Jun 15, 2023, 7:48 AM EDT - 2 years ago

Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It

Jun 12, 2023, 7:00 AM EDT - 2 years ago

BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease

Jun 1, 2023, 9:15 AM EDT - 2 years ago

Market Cap	13.36M
Revenue (ttm)	400,000.00
Net Income (ttm)	-8.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,245.00%
Debt to Equity Ratio	0.00

Volume	25,100
Avg Vol	455,832
Day's Range	N/A - N/A
Shares Out	7.51M
Stochastic %K	57%
Beta	68.90
Analysts	Strong Sell
Price Target	$13.00